ChemTrak Inc., of Sunnyvale, Calif., completed a privateplacement for up to $5 million in convertible debentures. The moneywill be used for development, manufacture and marketing of thecompany's personal diagnostic tests.

Digene Diagnostics Inc., of Silver Spring, Md., said its initialpublic offering of three million shares was priced at $11.50 each. Theshares were expected to go off between $11 and $13. The companymakes and markets genetic probe diagnostics. (See BioWorld Today,May 8, 1996, p. 3.)

International Murex Technologies Corp., of Atlanta, launched itsHIV antigen enzyme immunoassay, called the Murex HIV Antigen,in markets outside the U.S. The product detects and monitors the p24antigen of HIV.

Oncor Inc., of Gaithersburg. Md., said the FDA deemed thecompany's premarket approval application for the Oncor System forHuman Papilloma Virus (HPV) approvable subject to final labelingand inspection requirements. The system is a nucleic acidhybridization assay for detection and typing of HPV, which isassociated with increased risk of cervical cancer.

UroCor Inc., of Oklahoma City, completed an initial public offeringof 3.45 million shares, including the underwriters' option on 450,000shares, at $11 per share. The company provides diagnostic services tothe urology market. (See BioWorld Today, April 24, 1996, p. 3.)

(c) 1997 American Health Consultants. All rights reserved.